Clinical trials: Disorder, Mood
Schizophrenia, Major Depressive Disorder
"Brexpiprazole (Rexulti™) Safety and Efficacy Among Filipino Patients (RAISE) - A Post Marketing Surveillance Program"
The objective of this post marketing surveillance is to further gather local data on the safety and efficacy of Brexpiprazole (RexultiTM) Film-coated Tablet in the treatment of schizophrenia and adjunctive therapy of Major…
- Trial name
- RAISE (NCT04641780)
- Testing
- Brexpiprazole
- Where
- Philippines
- Volunteers
- 300 people
- Sponsor
- Otsuka Pharmaceutical, Inc., Philippines
Depressive Disorder, Major
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-911 in Healthy Subjects
This is a Phase 1, conventional, double-blind, placebo-controlled, single-center clinical study comprised of 2 segments (Segment 1 and Segment 2) in which single and multiple doses of SUVN-911 or placebo will be orally…
- Trial name
- SUVN-911 (NCT03155503)
- Testing
- SUVN-911
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Suven Life Sciences Limited
Major Depressive Disorder
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
This is a Double-blind Study Evaluating Desvenlafaxine Succinate (DVS SR) Sustained Release vs Placebo in the Treatment of Children and Adolescent Outpatients with Major Depressive Disorder (MDD).
- Trial name
- NCT01372150
- Testing
- desvenlafaxine succinate sustained release, fluoxetine
- Where
- 43 sites in United States, Mexico
- Volunteers
- 340 people
- Sponsor
- Pfizer
Bipolar Disorder
Lamictal as Add-on Treatment for Bipolar I Disorder in Pediatric Patients
The study will be a multi-center, parallel, group, placebo control, double-blind, randomized controlled trial of lamictal as add-on maintenance treatment in pediatric outpatients (aged 10 to 17 years) diagnosed with Bipolar I…
- Trial name
- NCT00723450
- Testing
- lamictal
- Where
- 46 sites in United States
- Volunteers
- 301 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms.
- Trial name
- NCT01436162
- Testing
- Antidepressant + SPD489 (Lisdexamfetamine dimesylate )
- Where
- 101 sites in United States, Belgium and 9 more
- Volunteers
- 1,105 people
- Sponsor
- Shire
Major Depressive Disorder
Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder
This randomized, double-blind, placebo-controlled, multicenter study will evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD).
- Trial name
- NCT06058039
- Testing
- NMRA-335140
- Where
- 71 sites in United States, Bulgaria and 6 more
- Volunteers
- 422 people
- Sponsor
- Neumora Therapeutics, Inc.
Major Depressive Disorder
Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER compared to placebo in patients with Major Depressive Disorder (MDD).
- Trial name
- NCT01377194
- Testing
- Levomilnacipran ER
- Where
- 51 sites in United States, Canada
- Volunteers
- 568 people
- Sponsor
- Forest Laboratories
Depressive Disorder, Major
A Study to Evaluate Pharmacokinetics, Safety and Tolerability of Extended-release Bupropion Hydrochloride Tablets in Chinese Healthy Volunteers
Bupropion is used in psychological disorder mainly in major depressive disorder (MDD). In China, buproprion Immediate Release (IR) and Sustained Release (SR) tablet have been in market for the treatment of MDD.
- Trial name
- NCT02698553
- Testing
- Bupropion HCl XL tablet 150mg, Bupropion HCl XL tablet 300mg
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder (MDD)
Effects Of Antidepressants On Sexual Functioning In Adults
This study will evaluate the effects of two antidepression medications on sexual functioning.
- Trial name
- NCT00051272
- Testing
- Extended-release Bupropion Hydrochloride
- Where
- 24 sites in United States
- Volunteers
- 425 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)
This is an outpatient, 2-arm, Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of REL-1017 once daily (QD) as a monotherapy for Major Depressive Disorder.
- Trial name
- Reliance III (NCT05081167)
- Testing
- REL-1017
- Where
- 10 sites in United States
- Volunteers
- 232 people
- Sponsor
- Relmada Therapeutics, Inc.
Depression, Major Depressive Disorder
Prediction of REsponse to Depression Interventions Using Clinical and TD-fNIRS Measurements
The purpose of the current study is to perform a unified, homogeneous data collection protocol that includes a large cohort of patients undergoing different treatment options for Major Depressive Disorder (MDD) as an avenue for…
- Trial name
- PREDICT (NCT06002100)
- Testing
- fNIRS measurement
- Where
- 10 sites in United States
- Volunteers
- 540 people
- Sponsor
- Kernel
Cognitive, Mood and Cognitive Performance
The Acute Effects of Onnit Alpha Brain on Cognition and Mood States
The purpose of this randomized, double-blind, placebo-controlled crossover study is to evaluate the efficacy of the acute effects of an investigational supplement (Alpha Brain or Alpha Brain 2.0) on improving cognitive…
- Conditions
- Cognitive, Mood and Cognitive Performance, Sleep Deprivation, Executive Function (Cognition)
- Trial name
- NCT07495592
- Testing
- Alpha Brain proprietary cognitive dietary supplement, Alpha Brain 2.0 proprietary cognitive dietary supplement
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Applied Science & Performance Institute
Bipolar Depression, Suicidal Ideation and Behavior
NRX-101 for Bipolar Depression With Subacute Suicidal Ideation
NMDA antagonist drugs have shown to reduce symptoms of depression and suicidal ideation. NeuroRx has developed NRX-101 (fixed dose combination of D-cycloserine and lurasidone) for oral use in the treatment of bipolar depression…
- Trial name
- NCT03395392
- Testing
- NRX-101, Lurasidone HCl
- Where
- 14 sites in United States
- Volunteers
- 74 people
- Sponsor
- NeuroRx, Inc.
Major Depressive Disorder
Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder
This study will evaluate the long-term safety and tolerability of escitalopram (Lexapro) in children 7 to 11 years of age with major depressive disorder (MDD).
- Trial name
- NCT01198795
- Testing
- Escitalopram
- Where
- 16 sites in United States
- Volunteers
- 162 people
- Sponsor
- Forest Laboratories
Depressive Disorder, Treatment-Resistant
A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression
The purpose of this study is to evaluate how well each individual dose of esketamine (56 milligrams [mg] and 84 mg) works when compared with placebo in improving depressive symptoms in participants with treatment resistant…
- Trial name
- NCT07716098
- Testing
- Esketamine 56 mg, Esketamine 84 mg
- Where
- 39 sites in United States, China and 2 more
- Volunteers
- 348 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder, Major
A Clinical Trial for the Treatment of Depression With Repetitive Transcranial Magnetic Stimulation (rTMS)
The purpose of this study is to determine whether the Cervel Neurotech rTMS device is safe and effective in the treatment of depression in people who do not get better with antidepressant medications or cannot take antidepressant…
- Trial name
- NCT01909232
- Testing
- Active Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator, Inactive Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator
- Where
- 6 sites in United States
- Volunteers
- 92 people
- Sponsor
- Cervel Neurotech, Inc.
Major Depressive Disorder
An Open-label, Adaptive Design, Positron Emission Tomography Study in Healthy Male Participants to Characterize Receptor Occupancy by MIJ821 in the Brain
The purpose of this study is to confirm binding of MIJ821 to the NR2B-containing NMDA receptors in the human brain and assess the PC-RO relationship over time using positron emission tomography (PET).
- Trial name
- NCT05666687
- Testing
- MIJ821
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Treatment Resistant Depression
Studying Patterns in Patient Engagement Among Treatment Resistant Depression Patients
Clinical studies, with a distinct focus on treatment resistant depression, play a crucial role in evaluating the safety and effectiveness of novel treatments.
- Trial name
- NCT06101914
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Major Depressive Disorder
To Evaluate the Long-term Efficacy and Safety of Toludevenlafaxine Hydrochloride Sustained-release Tablets
This is a multicenter, randomized withdrawal, double-blind, parallel, placebo-controlled design clinical trial of Toludesvenlafaxine Hydrochloride Extended-Release Tablets to evaluate the long-term efficacy and safety in the…
- Trial name
- NCT06426485
- Testing
- Toludesvenlafaxine Hydrochloride Sustained-release Tablets
- Volunteers
- 736 people
- Sponsor
- Luye Pharma Group Ltd.
Depressive Disorder, Major
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
The purpose of this study is to assess the efficacy of Seltorexant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in participants with major depressive disorder with insomnia…
- Trial name
- NCT04532749
- Testing
- Seltorexant
- Where
- 80 sites in United States, Argentina and 8 more
- Volunteers
- 212 people
- Sponsor
- Janssen Research & Development, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.